Shire’s Prucalopride Brings Real-World CV Safety Data To US FDA Panel, But Will It Be Enough?

European postmarketing epidemiological study results ‘reasonably exclude’ a greater than three-fold increased risk of major adverse cardiovascular events with the constipation drug but, due to potential bias, cannot definitively exclude a possibly unacceptable level of risk, agency says.